The agency said it received an adverse event report on August 14 from a physician whose patient was diagnosed postoperatively with bilateral HORV after being administered injections of a compounded triamcinolone,
moxifloxacin, and vancomycin (TMV) formulation in each eye after cataract procedures that were done 2 weeks apart. Imprimis Pharmaceuticals, Inc, of Ledgewood, New Jersey, had compounded the TMV.